Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
qncx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Quince Therapeutics, Inc. (QNCX) measures how much investors pay for each dollar of the company's trailing earnings. QNCX's current PE ratio of N/A is calculated by dividing its stock price of $1.00 by its TTM earnings per share of -$6.59.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Quince Therapeutics, Inc.You QNCX | $6M | N/A | — | -$6.59 |
 Adverum Biotechnologies, Inc. ADVM | $96M | N/A | — | -$6.62 |
 ALX Oncology Holdings Inc. ALXO | $211M | N/A | — | -$1.90 |
 aTyr Pharma, Inc. ATYR | $43M | N/A | — | -$0.80 |
 CAMP4 Therapeutics Corporation CAMP | $87M | N/A | — | -$2.65 |
 Connect Biopharma Holdings Limited CNTB | $139M | N/A | — | -$1.00 |
 Precision BioSciences, Inc. DTIL | $87M | N/A | — | -$3.63 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-16.76 | — | |
2024-12-31 FY2024 | — | $-13.14 | — | |
2023-12-31 FY2023 | — | $-8.43 | — | |
2022-12-31 FY2022 | — | $-15.42 | — | |
2021-12-31 FY2021 | — | $-30.27 | — | |
2020-12-31 FY2020 | — | $-26.34 | — | |
2019-12-31 FY2019 | — | $-19.43 | — | |
2018-12-31 FY2018 | — | $-5.79 | — | |
2017-12-31 FY2017 | — | $-5.68 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Quince Therapeutics, Inc. (QNCX) measures how much investors pay for each dollar of the company's trailing earnings. QNCX's current PE ratio of N/A is calculated by dividing its stock price of $1.00 by its TTM earnings per share of -$6.59.
Frequently asked questions
QNCX pe ratio · 6 questionsQNCX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.00 and TTM EPS of -$6.59. Data sourced from Financial Modeling Prep via QNCX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Quince Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09